EU's CHMP endorses Novartis's Menveo
This article was originally published in Scrip
Executive Summary
The EU's CHMP has recommended that Novartis's conjugated vaccine Menveo (meningococcal group A, C, W-135 and Y-CRM conjugate vaccine) be approved for the immunisation of people aged over 11 years at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.